COVID-19 in Baselland: Investigation and Validation of Serological Diagnostic Assays and Epidemiological Study of Sars-CoV-2 Specific Antibody Responses

  • STATUS
    Recruiting
  • participants needed
    550
  • sponsor
    University Hospital, Basel, Switzerland
Updated on 19 February 2024
antibody test
covid-19
SARS
acute respiratory syndrome (sars)

Summary

The study is to investigate the antibody response in the blood and saliva of people with a known COVID-19 infection in the canton of Baselland.

Description

This study is to analyse the antibody response in the blood and saliva of people with a known COVID-19 infection in the canton of Baselland.

The study aims to validate strategies to measure antibody levels with minimal intervention and to explore the antibody response and technical capacity for said measurement. The study will collect the minimally necessary samples to deduce a strategy for serum or saliva surveillance of the population of the canton Baselland. To achieve this, the study is designed to address the following points:

  • determine specificity, sensitivity and general utility of point of care (POC) and ELISA tests to deduce a strategy for serum surveillance of the population of the canton Baselland
  • especially validate different POC kits in regard of their use for continuous surveillance
  • gain an understanding of seroconversion and antibody levels of patients and survivors
  • gain an understanding of the individual antibody and T-cell repertoire of patients and survivors
  • study whether patterns of convergent antibody evolution is generated in the surviving population or whether the diseases survivors generated an antibody pool recognizing a specific epitope
  • develop the technology to correlate blood antibody levels with levels detected in the saliva
  • develop high throughput technologies for the precise detection of immune cell Repertoire and binding epitopes

Details
Condition COVID-19 Infection
Age 18years - 100years
Treatment Blood Draw, Saliva collection, fingertip tests for POC assays, collection of swabs
Clinical Study IdentifierNCT04483908
SponsorUniversity Hospital, Basel, Switzerland
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

tested positive for COVID-19 in Baselland
tested negative for COVID-19 in Baselland. Specifically, needed to show symptoms to be able to deduce cross reactivities

Exclusion Criteria

continuous steroid therapy / chemotherapy / immunsuppressiva
subject is treated for cancer
severe autoimmune disease
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study AnnotationsStudy Notes

Notes added here are public and can be viewed by anyone. Notes added here are only available to you and those who you share with.

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.